Bavarian Nordic EVP on Covid-19 vaccine: "We couldn't have wished for better data"

On Sunday, Bavarian Nordic unveiled data from its phase II study of its Covid-19 vaccine, ABNCoV2. According to Bavarian Nordic's EVP & CIO, the data was the best-case scenario.

Photo: PR / Bavarian Nordic

Phase II data from Bavarian Nordic's Covid-19 vaccine, ABNCoV2, compares well with known mRNA vaccines from Pfizer/Biontech and US-based Moderna, Executive Vice President and Chief Financial Officer Henrik Juuel tells MarketWire in an interview.

However, he points out that one must exercise caution when comparing across studies, as the vaccines haven't been tested against each other directly.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs